Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/IGHM_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IGHM_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/IGHM_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IGHM_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/IGHM_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IGHM_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00512519 | Thyroid | HT | positive regulation of lymphocyte activation | 51/1272 | 362/18723 | 5.57e-07 | 2.38e-05 | 51 |
GO:000269610 | Thyroid | HT | positive regulation of leukocyte activation | 55/1272 | 409/18723 | 9.17e-07 | 3.70e-05 | 55 |
GO:00508679 | Thyroid | HT | positive regulation of cell activation | 55/1272 | 420/18723 | 2.11e-06 | 7.61e-05 | 55 |
GO:00160644 | Thyroid | HT | immunoglobulin mediated immune response | 32/1272 | 207/18723 | 1.05e-05 | 2.82e-04 | 32 |
GO:00197244 | Thyroid | HT | B cell mediated immunity | 32/1272 | 210/18723 | 1.42e-05 | 3.57e-04 | 32 |
GO:00024494 | Thyroid | HT | lymphocyte mediated immunity | 45/1272 | 350/18723 | 2.76e-05 | 6.05e-04 | 45 |
GO:00022536 | Thyroid | HT | activation of immune response | 47/1272 | 375/18723 | 3.55e-05 | 7.40e-04 | 47 |
GO:00069564 | Thyroid | HT | complement activation | 22/1272 | 130/18723 | 6.17e-05 | 1.16e-03 | 22 |
GO:00069598 | Thyroid | HT | humoral immune response | 40/1272 | 317/18723 | 1.14e-04 | 1.86e-03 | 40 |
GO:00024434 | Thyroid | HT | leukocyte mediated immunity | 51/1272 | 440/18723 | 1.30e-04 | 2.07e-03 | 51 |
GO:00080371 | Thyroid | HT | cell recognition | 31/1272 | 225/18723 | 1.35e-04 | 2.12e-03 | 31 |
GO:00024605 | Thyroid | HT | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 43/1272 | 356/18723 | 1.74e-04 | 2.59e-03 | 43 |
GO:00421133 | Thyroid | HT | B cell activation | 39/1272 | 334/18723 | 6.66e-04 | 7.61e-03 | 39 |
GO:00069583 | Thyroid | HT | complement activation, classical pathway | 17/1272 | 108/18723 | 9.56e-04 | 9.83e-03 | 17 |
GO:00027648 | Thyroid | HT | immune response-regulating signaling pathway | 50/1272 | 468/18723 | 9.96e-04 | 1.02e-02 | 50 |
GO:00024552 | Thyroid | HT | humoral immune response mediated by circulating immunoglobulin | 18/1272 | 121/18723 | 1.35e-03 | 1.29e-02 | 18 |
GO:00069094 | Thyroid | HT | phagocytosis | 34/1272 | 308/18723 | 3.59e-03 | 2.73e-02 | 34 |
GO:00103244 | Thyroid | HT | membrane invagination | 19/1272 | 144/18723 | 4.08e-03 | 2.99e-02 | 19 |
GO:00508643 | Thyroid | HT | regulation of B cell activation | 24/1272 | 198/18723 | 4.18e-03 | 3.05e-02 | 24 |
GO:00990243 | Thyroid | HT | plasma membrane invagination | 18/1272 | 136/18723 | 4.93e-03 | 3.35e-02 | 18 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGHM | SNV | Missense_Mutation | novel | c.254A>T | p.His85Leu | p.H85L | | IG_C_gene | tolerated(0.35) | unknown(0) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
IGHM | SNV | Missense_Mutation | novel | c.337N>A | p.Val113Met | p.V113M | | IG_C_gene | tolerated(0.14) | unknown(0) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
IGHM | insertion | Frame_Shift_Ins | novel | c.82_83insCCCAAAGTGAGCGTCTTCGTCCC | p.Cys28SerfsTer41 | p.C28Sfs*41 | | IG_C_gene | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
IGHM | SNV | Missense_Mutation | novel | c.851N>T | p.Ala284Val | p.A284V | | IG_C_gene | tolerated(0.79) | possibly_damaging(0.691) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IGHM | SNV | Missense_Mutation | novel | c.122N>T | p.Ser41Phe | p.S41F | | IG_C_gene | deleterious(0) | unknown(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IGHM | SNV | Missense_Mutation | rs372720307 | c.1172N>A | p.Arg391Gln | p.R391Q | | IG_C_gene | tolerated(0.27) | benign(0.412) | TCGA-EA-A50E-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
IGHM | SNV | Missense_Mutation | rs372261472 | c.76G>A | p.Val26Ile | p.V26I | | IG_C_gene | tolerated(0.65) | unknown(0) | TCGA-FU-A5XV-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
IGHM | SNV | Missense_Mutation | novel | c.346T>C | p.Phe116Leu | p.F116L | | IG_C_gene | tolerated(0.18) | unknown(0) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGHM | SNV | Missense_Mutation | rs375873260 | c.905C>T | p.Thr302Met | p.T302M | | IG_C_gene | tolerated(0.07) | possibly_damaging(0.895) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
IGHM | SNV | Missense_Mutation | rs782615938 | c.853N>A | p.Val285Met | p.V285M | | IG_C_gene | tolerated(0.12) | possibly_damaging(0.788) | TCGA-AA-3673-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |